Why Is Breztri So Hard to Find? [Explained for 2026]

If you have COPD and your doctor prescribed Breztri Aerosphere, you may have run into a frustrating reality: it's not always easy to find at your local pharmacy. You're not imagining things. Many patients with chronic obstructive pulmonary disease (COPD) report driving from pharmacy to pharmacy or waiting days for their inhaler to be ordered. In this guide, we explain exactly why Breztri is hard to find — and what you can do to get your prescription filled without delay.

What Is Breztri Aerosphere?

Breztri Aerosphere is a triple-combination inhaler made by AstraZeneca. It contains three active medications in a single pressurized metered-dose inhaler: budesonide (an inhaled corticosteroid, or ICS), glycopyrrolate (a long-acting muscarinic antagonist, or LAMA), and formoterol fumarate (a long-acting beta2-adrenergic agonist, or LABA). The FDA first approved it in July 2020 for the maintenance treatment of COPD in adults. In April 2026, the FDA also approved Breztri as the first single-inhaler triple therapy for asthma in patients aged 12 and older.

Because all three medications work through different but complementary pathways — fighting inflammation, relaxing airway muscles, and blocking the signals that tighten airways — Breztri can deliver better breathing control than most dual-therapy inhalers. Clinical trials showed it reduced the annual rate of moderate or severe COPD exacerbations by 24% compared to LAMA/LABA therapy and 13% compared to ICS/LABA therapy. No wonder demand is high.

Is There an Actual Breztri Shortage?

As of 2026, Breztri Aerosphere is not listed on the FDA's official drug shortage database. That means there is no declared nationwide manufacturing shortage from AstraZeneca. However, that doesn't mean it's easy to walk into any pharmacy and pick up your inhaler. Many patients across the United States continue to experience localized difficulty filling their Breztri prescriptions.

This gap between "no official shortage" and real-world availability comes down to several factors that stack against patients at the pharmacy level.

Why Is Breztri So Hard to Find at Pharmacies?

Here are the main reasons Breztri Aerosphere is difficult to stock and fill at many pharmacies:

1. No Generic Version Exists

Breztri Aerosphere is a brand-name-only medication. There is no generic equivalent on the market, and none is expected until around 2038 due to AstraZeneca's patent protection. When there's only one source for a drug — a single manufacturer and a limited distribution network — any hiccup in supply creates a bottleneck with no backup option. This is fundamentally different from a drug like metformin, where dozens of generic manufacturers fill the gap when one supplier has problems.

2. Surging Demand for Triple-Therapy Inhalers

Triple-therapy inhalers like Breztri and Trelegy Ellipta are among the most prescribed maintenance inhalers in the United States, and that number is growing. More pulmonologists and primary care providers are stepping up COPD patients from dual therapy to triple therapy as clinical evidence demonstrates better exacerbation reduction. Breztri's new 2026 approval for asthma in patients 12 and older will only accelerate this trend. Higher demand means pharmacy shelves deplete faster, especially at smaller or independent pharmacies that don't carry large stock.

3. Insurance and Prior Authorization Delays

Most insurance plans require prior authorization before covering Breztri Aerosphere. This means your doctor must submit documentation showing you meet the criteria for triple therapy — usually that you've tried and failed dual-therapy inhalers first. Step therapy requirements are also common: many plans won't cover Breztri until you've tried a cheaper alternative. These administrative delays can make it feel like you can't fill your prescription even when the inhaler is physically on the shelf.

4. High Cash Price Without Insurance

Without insurance, a single Breztri Aerosphere inhaler (a 30-day supply when used as prescribed) retails for roughly $670 to $930 depending on the pharmacy. Even with a GoodRx or SingleCare discount, patients typically pay $572–$674 out of pocket. For patients on fixed incomes or without commercial insurance, this price point makes Breztri effectively inaccessible — creating a situation that looks a lot like a shortage, even when stock is available.

5. Uneven Distribution Across Pharmacy Chains

Different pharmacy chains source medications from different distributors. One CVS location may have Breztri in stock while another CVS four miles away doesn't. An independent pharmacy may have a different supply chain entirely. This uneven distribution — not a true shortage — means calling ahead or checking availability before you go is essential.

What Can You Do If Your Pharmacy Doesn't Have Breztri?

Here are the most effective steps to take when you can't find Breztri at your local pharmacy:

Use medfinder — medfinder calls pharmacies near you to find out which ones have Breztri in stock, saving you hours of phone calls.

Try independent or specialty pharmacies — they sometimes have different supply chains than major retail chains.

Request refills 7–14 days early so your pharmacy has time to order if they're out of stock.

Ask your pharmacist about a 90-day supply through your insurance's mail-order pharmacy program.

Ask your doctor about the AstraZeneca Zero Pay program if you have commercial insurance — eligible patients may pay $0 per fill.

Could Breztri Ever Face a True Shortage?

It's possible. AstraZeneca manufactures all of the global Breztri supply. If there were a manufacturing disruption, supply chain issue, or major distribution delay, patients could face a genuine shortage with no generic fallback. That's exactly the situation Trelegy Ellipta patients have experienced at times. The best protection is to manage your refills early and keep a communication line open with your prescriber.

When Should You Talk to Your Doctor About Alternatives?

If you're consistently unable to fill Breztri and running low on your supply, don't wait. Contact your prescriber immediately. Alternative triple-therapy options, like Trelegy Ellipta, may be covered differently on your insurance plan. Dual-therapy options with generic versions (like generic Symbicort) can serve as a bridge. Read our full guide on alternatives to Breztri if you can't fill your prescription for a complete comparison.

The Bottom Line

Breztri isn't in a declared shortage — but its brand-name-only status, surging demand, and insurance hurdles combine to make it genuinely difficult for many patients to fill. The good news is that with the right strategy — filling early, calling multiple pharmacies, and using services like medfinder — most patients can get their prescription filled. For a step-by-step guide on locating Breztri in stock near you, read how to find Breztri in stock near you.